Off-label drug use in dermatology

Background In 2010, 1% of our pharmaceutical expenditure corresponded to off-label use, except for cytostatics. The dermatology department has increased drug costs due to the off-label use. Purpose To assess the applications and costs of off-label drug use in dermatology. To check the therapeutic results obtained and the number of available reports. Materials and methods The authors reviewed off-label requests from Dermatology during 2009 and 2010. The authors reviewed the reports compiled in Medline from 1997 to 2010 and classified according to reported cases number in N 100. The results were classified as effective if dermatologists achieved the therapeutic objective, partially effective if they reached the initial objective at least in 50% and ineffective when they didn9t achieved the therapeutic purpose. Results In 2009, 95 drugs were requested for an off-label use representing 404,909 €; 7 were requests from Dermatology at a cost of 49,218 €. In 2010, 134 drugs were requested for off-label use representing 410,716 €; 5 were requests from Dermatology represented 117,565 €. Conclusions During 2010 there was an increase in the cost of off-label use in dermatology due to lenalidomide. Half of the treatments were effective, 25% partially effective and 25% ineffective. One third of the requests were supported by fewer than 10 reported cases.